{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:20:31Z","timestamp":1786119631758,"version":"build-2736575974"},"reference-count":42,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1097\/jcp.0b013e3181f28dff","type":"journal-article","created":{"date-parts":[[2010,9,2]],"date-time":"2010-09-02T08:13:40Z","timestamp":1283415220000},"page":"518-525","source":"Crossref","is-referenced-by-count":26,"title":["A Randomized, Double-Blind Comparison of Risperidone Versus Low-Dose Risperidone Plus Low-Dose Haloperidol in Treating Schizophrenia"],"prefix":"10.1097","volume":"30","author":[{"given":"Ching-Hua","family":"Lin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao-Chan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Shiu","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yeng-Hung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Chung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuo-Hao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsien-Yuan","family":"Lane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/sj.mp.4001556","article-title":"Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs.","volume":"10","author":"Miyamoto","year":"2005","journal-title":"Mol Psychiatry"},{"key":"R2-6-20210128","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R3-6-20210128","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archpsyc.60.6.553","article-title":"A meta-analysis of the efficacy of second-generation antipsychotics.","volume":"60","author":"Davis","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"R4-6-20210128","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1097\/01.jcp.0000144895.75728.2b","article-title":"Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study.","volume":"24","author":"Ritsner","year":"2004","journal-title":"J Clin Psychopharmacol"},{"key":"R5-6-20210128","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1056\/NEJMoa051688","article-title":"Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.","volume":"353","author":"Lieberman","year":"2005","journal-title":"N Engl J Med"},{"key":"R6-6-20210128","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1471-244X-5-26","article-title":"Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics.","volume":"5","author":"Faries","year":"2005","journal-title":"BMC Psychiatry"},{"key":"R7-6-20210128","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1093\/oxfordjournals.schbul.a006912","article-title":"Combination antipsychotics: pros, cons, and questions.","volume":"28","author":"Miller","year":"2002","journal-title":"Schizophr Bull"},{"key":"R8-6-20210128","first-page":"67","article-title":"Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia.","volume":"6","author":"Loosbrock","year":"2003","journal-title":"J Ment Health Policy Econ"},{"key":"R9-6-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/pds.783","article-title":"Antipsychotic medication coprescribing in a large state hospital system.","volume":"12","author":"Jaffe","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R10-6-20210128","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.4088\/JCP.v65n1013","article-title":"Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000.","volume":"65","author":"Ganguly","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R11-6-20210128","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1176\/appi.ajp.161.4.700","article-title":"Multiple versus single antipsychotic agents for hospitalized psychiatric patients: case-control study of risks versus benefits.","volume":"161","author":"Centorrino","year":"2004","journal-title":"Am J Psychiatry"},{"key":"R12-6-20210128","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/oxfordjournals.schbul.a006928","article-title":"Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy.","volume":"28","author":"Clark","year":"2002","journal-title":"Schizophr Bull"},{"key":"R13-6-20210128","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1176\/appi.ps.54.1.55","article-title":"Combination antipsychotic therapy in clinical practice.","volume":"54","author":"Tapp","year":"2003","journal-title":"Psychiatr Serv"},{"key":"R14-6-20210128","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1345\/aph.1C420","article-title":"Multiple antipsychotic medication prescribing patterns.","volume":"37","author":"Schumacher","year":"2003","journal-title":"Ann Pharmacother"},{"key":"R15-6-20210128","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1001\/archpsyc.1991.01810320063009","article-title":"Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose.","volume":"48","author":"McEvoy","year":"1991","journal-title":"Arch Gen Psychiatry"},{"key":"R16-6-20210128","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1176\/ajp.156.2.286","article-title":"Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia.","volume":"156","author":"Kapur","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R20-6-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1001\/archpsyc.1988.01800330013001","article-title":"Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.","volume":"45","author":"Kane","year":"1988","journal-title":"Arch Gen Psychiatry"},{"key":"R21-6-20210128","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R22-6-20210128","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0920-9964(94)90017-5","article-title":"Specificity of the Calgary Depression Scale for schizophrenics.","volume":"11","author":"Addington","year":"1994","journal-title":"Schizophr Res"},{"key":"R23-6-20210128","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1176\/appi.ps.53.6.730","article-title":"Global Assessment of Functioning ratings and the allocation and outcomes of mental health services.","volume":"53","author":"Moos","year":"2002","journal-title":"Psychiatr Serv"},{"key":"R24-6-20210128","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia.","volume":"154","author":"Barnes","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R25-6-20210128","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects.","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr Scand"},{"issue":"suppl","key":"R26-6-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1600-0447.1987.tb10566.x","article-title":"The UKU Side Effect Rating Scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients.","volume":"334","author":"Lingjaerde","year":"1987","journal-title":"Acta Psychiatr Scand"},{"key":"R27-6-20210128","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1136\/bmj.305.6846.160","article-title":"Validating the SF-36 health survey questionnaire: new outcome measure for primary care.","volume":"305","author":"Brazier","year":"1992","journal-title":"BMJ"},{"key":"R28-6-20210128","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.4088\/JCP.v67n0712","article-title":"Comparison of quetiapine and risperidone in the treatment of schizophrenia: a randomized, double-blind, flexible-dose, 8-week study.","volume":"67","author":"Zhong","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R30-6-20210128","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1176\/ajp.156.6.869","article-title":"Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.","volume":"156","author":"Nyberg","year":"1999","journal-title":"Am J Psychiatry"},{"key":"R31-6-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0024-3205(95)02037-J","article-title":"The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study.","volume":"57","author":"Kapur","year":"1995","journal-title":"Life Sci"},{"key":"R32-6-20210128","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.4088\/JCP.v67n1120","article-title":"Measurement-based psychiatry: definitions of response, remission, stability, and relapse in schizophrenia.","volume":"67","author":"Leucht","year":"2006","journal-title":"J Clin Psychiatry"},{"key":"R33-6-20210128","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1001\/archpsyc.62.11.1196","article-title":"Sarcosine or d-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.","volume":"62","author":"Lane","year":"2005","journal-title":"Arch Gen Psychiatry"},{"key":"R34-6-20210128","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s00213-004-1866-y","article-title":"Combined treatment of quetiapine with haloperidol in animal models of antipsychotic effect and extrapyramidal side effects: comparison with risperidone and chlorpromazine.","volume":"176","author":"Tada","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R35-6-20210128","doi-asserted-by":"crossref","first-page":"209","DOI":"10.4088\/JCP.v61n0311","article-title":"Risperidone in acutely exacerbated schizophrenia: dosing strategies and plasma levels.","volume":"61","author":"Lane","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"R36-6-20210128","doi-asserted-by":"crossref","first-page":"282","DOI":"10.4088\/JCP.v62n0411","article-title":"Optimal dosing with risperidone: updated recommendations.","volume":"62","author":"Williams","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"R37-6-20210128","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1177\/0269881105057001","article-title":"Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia.","volume":"20","author":"Ezewuzie","year":"2006","journal-title":"J Psychopharmacol"},{"key":"R38-6-20210128","doi-asserted-by":"crossref","first-page":"663","DOI":"10.4088\/JCP.v64n0607","article-title":"Chlorpromazine equivalent doses for the newer atypical antipsychotics.","volume":"64","author":"Woods","year":"2003","journal-title":"J Clin Psychiatry"},{"key":"R39-6-20210128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0022-3956(98)00023-5","article-title":"New atypical antipsychotic medications.","volume":"32","author":"Jibson","year":"1998","journal-title":"J Psychiatr Res"},{"key":"R40-6-20210128","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1176\/appi.ajp.159.11.1932","article-title":"Inpatient antipsychotic drug use in 1998, 1993, and 1989.","volume":"159","author":"Centorrino","year":"2002","journal-title":"Am J Psychiatry"},{"key":"R41-6-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.4088\/JCP.v65n0109","article-title":"Prolactin levels in schizophrenia and schizoaffective disorder patients treated with clozapine, olanzapine, risperidone, or haloperidol.","volume":"65","author":"Volavka","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"R42-6-20210128","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1124\/jpet.102.035303","article-title":"The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats.","volume":"302","author":"Kapur","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"R43-6-20210128","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s00213-004-1826-6","article-title":"Prolactinemia is uncoupled from central D2\/D3 dopamine receptor occupancy in amisulpride treated patients.","volume":"175","author":"Bressan","year":"2004","journal-title":"Psychopharmacology (Berl)"},{"key":"R44-6-20210128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/00004714-199902000-00011","article-title":"Prolactin levels and adverse events in patients treated with risperidone.","volume":"19","author":"Kleinberg","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R47-6-20210128","doi-asserted-by":"crossref","first-page":"829","DOI":"10.4088\/JCP.08m04905","article-title":"Lurasidone in the treatment of acute schizophrenia: a double-blind, placebo-controlled trial.","volume":"70","author":"Nakamura","year":"2009","journal-title":"J Clin psychiatry"},{"key":"R48-6-20210128","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s004060070041","article-title":"Five-factor model of schizophrenic psychopathology: how valid is it?","volume":"250","author":"Lykouras","year":"2000","journal-title":"Eur Arch Psychiatry Clin Neurosci"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004714-201010000-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:37:14Z","timestamp":1786041434000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004714-201010000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e3181f28dff","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}